8-K: Qualigen Therapeutics Pivots to Crypto with $41M Faraday Future-Led PIPE

Qualigen Therapeutics, Inc. announced a $41 million private investment led by Faraday Future Intelligent Electric Inc. to pivot its business towards cryptocurrency and Web3, alongside significant corporate governance and management changes.

Summary

• Qualigen Therapeutics, Inc. (QLGN) entered into a Subscription Agreement for a Private Investment in Public Equity (PIPE) totaling approximately $41 million.
• The PIPE is led by Faraday Future Intelligent Electric Inc. (FFAI) and its Founder and Global Co-CEO YT Jia, with other investors including SIGN Foundation.
• Faraday Future will invest approximately $30 million, gaining beneficial ownership of about 55% of QLGN's outstanding common stock.
• YT Jia will personally invest approximately $4 million, acquiring about 7% ownership, and has agreed to a two-year voluntary lock-up on his personal investment.
• The total beneficial ownership for Faraday Future and YT Jia is expected to exceed 62% post-transaction.
• Proceeds: Up to $6.8 million for existing debt and business operations; the balance for establishing cryptocurrency treasury operations and purchasing cryptocurrencies.
• The company expects to rebrand as CXC10, focusing entirely on crypto and Web3, upon obtaining stockholder approval.
• The transaction involves the issuance of Common Stock at $2.246 per share and Series B Convertible Preferred Stock at a stated value of $1,000 per share, convertible into common stock at $2.246 per share.
• Stockholder approval is required for the issuance of conversion shares exceeding the 19.99% Exchange Cap under Nasdaq rules and for shares issued to certain advisors.
• Existing Series A-2 Convertible Preferred Stock holders have agreed to vote in favor of the stockholder approval.

Sentiment

Score: 3

Explanation: The filing details a complete and highly speculative business pivot from therapeutics to cryptocurrency/Web3, which is an extremely high-risk move for a company of this profile. While a significant capital injection is secured, it comes with substantial dilution, high costs, and a transfer of significant control to the lead investor. The inherent volatility and regulatory uncertainty of the crypto market, combined with the company's lack of prior experience in this sector, present considerable downside risks for existing shareholders. The positive aspect is the capital raise itself and the clear strategic direction, but the risk profile is dramatically elevated.

Positives

• Secured a significant capital infusion of $41 million, addressing potential liquidity needs.
• Strategic pivot to the high-growth cryptocurrency and Web3 sector, potentially unlocking new growth avenues.
• Strong backing from a notable lead investor, Faraday Future, and its founder, lending credibility and strategic direction to the new business focus.
• YT Jia's personal investment and two-year lock-up demonstrate confidence in the new strategy.
• The new structure allows Faraday Future to focus on its EV strategy while QLGN drives crypto growth, potentially creating 'Dual Flywheel synergy and Dual Bridge empowerment'.
• The Series B Preferred Stock includes liquidation preference and strong anti-dilution/protection features for holders.
• Commitment from existing Series A-2 Preferred Stockholders to support the transaction.

Negatives

• Significant change in business direction (from therapeutics to crypto) introduces new, potentially higher, risks and requires a completely different operational expertise.
• The transaction involves substantial dilution for existing common stockholders, with Faraday Future and YT Jia gaining over 62% beneficial ownership.
• The conversion of Series B Preferred Stock is subject to a 19.99% Exchange Cap until stockholder approval, potentially limiting liquidity for preferred holders in the short term.
• The company is obligated to hold multiple stockholder meetings every 90 days if initial stockholder approval is not obtained, incurring ongoing costs and uncertainty.
• The Placement Agent will receive a 5.5% cash fee and warrants for 6% of the securities sold, representing a notable cost of capital.
• The Lead Investor gains significant control over corporate governance and management, including board seats and key executive appointments, potentially reducing autonomy for existing management and board.
• The FF-Appointed Co-CEO will have 'sole access to all crypto-related accounts of the Company' and be the 'sole individual authorized to execute such agreements on behalf of the Company' for new business affairs, which is a high concentration of control.

Risks

• Regulatory Uncertainty: The inherent volatility and regulatory uncertainty associated with cryptocurrency investments.
• Execution Risk: The Company’s ability to successfully execute on a new crypto-based strategy.
• Capital Raising Risk: The Company’s ability to raise funds to support a new crypto-based strategy.
• Market Volatility: Inherent volatility associated with cryptocurrency investments.
• Litigation Risk: Current and potential litigation involving the Company.
• Financing Efforts Failure: The result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code.
• General Economic Conditions: General economic and market conditions impacting demand for the Company’s products.
• External Factors: Circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest.
• Technology Protection: The Company’s ability to develop and protect its technologies.
• Stockholder Approval Risk: Failure to obtain required stockholder approval for the issuance of conversion shares and other transactions, potentially delaying or hindering the full implementation of the new strategy.
• Delisting Risk: The company's ability to maintain Nasdaq listing compliance, especially with the significant change in business.

Future Outlook

The company intends to pivot its business strategy to fully focus on cryptocurrency and Web3, rebranding as CXC10 upon stockholder approval. This new strategy, termed 'Dual Flywheel synergy and Dual Bridge empowerment,' aims to connect EAI with crypto and bridge Web2 with Web3. The company plans to establish cryptocurrency treasury operations and purchase additional cryptocurrencies, subject to market conditions and business needs. Faraday Future's FX strategy aims to introduce mass production EV models with luxury technology, targeting a broader market.

Management Comments

• "This strategic investment represents an important milestone in our evolution. I believe that FFAI will truly become a company powered by Dual Flywheel synergy and Dual Bridge empowerment—connecting EAI with crypto, and bridging Web2 with Web3." YT Jia, Founder and Global Co-CEO of Faraday Future.
• "This is a very exciting day for all stakeholders of Qualigen Therapeutics. The company will be embracing the new economy and technology which will reshape the future. The board unanimously voted to move forward with this transformative transaction and stand behind the leadership FF brings to our company." Kevin A. Richardson, CEO of QLGN.

Industry Context

This announcement signifies a dramatic shift for Qualigen Therapeutics from the biotechnology/pharmaceutical sector to the rapidly evolving and highly speculative cryptocurrency and Web3 industry. This move is counter to traditional industry trends for a therapeutics company and places QLGN in a nascent, volatile, and less regulated market. For Faraday Future, this allows them to leverage their founder's vision and potentially unlock new financing channels and maximize stockholder value for crypto-related business without further diluting FFAI stockholders for their core EV business. The involvement of a blockchain technology company like SIGN Foundation indicates a serious intent to build infrastructure within the Web3 space, aligning with broader tech trends but diverging sharply from QLGN's historical operations.

Comparison to Industry Standards

• Business Model Shift: This is an extreme deviation from industry standards for a therapeutics company. Most companies in the biotech/pharma sector focus on R&D, clinical trials, and commercialization of medical products. A pivot to crypto/Web3 is unprecedented for a company of QLGN's former profile and cannot be directly compared to typical industry benchmarks for either sector.
• Capital Raise Structure: The PIPE structure with convertible preferred stock and warrants is a common method for private capital raises in public companies, especially those seeking significant funding or undergoing strategic shifts. The terms (e.g., 135% redemption premium on Series B upon triggering events) are designed to provide strong protection for investors in high-risk ventures.
• Valuation: The effective common stock price of $2.246 per share and the conversion price of $2.246 for Series B Preferred Stock would need to be compared to QLGN's recent trading prices and industry-specific valuation metrics (e.g., P/S, P/B for crypto companies, or biotech valuations if still relevant) to assess if it's favorable. Without QLGN's current stock price, a direct comparison is not possible.
• Governance Changes: Granting significant board control (up to 4 out of 7 seats) and key executive roles (Co-CEO, CFO) to the lead investor is typical for a substantial strategic investment that fundamentally alters the company's direction, especially when the lead investor takes a majority beneficial ownership stake.
• Crypto Treasury Strategy: While some large corporations (e.g., MicroStrategy, Tesla) have adopted Bitcoin as a treasury reserve asset, a full pivot to 'cryptocurrency treasury operations' as a primary business focus for a former therapeutics company is highly unusual and carries extreme risk compared to traditional corporate treasury management.

Management Changes

Corporate Governance

Legal Proceedings

• The press release mentions 'Current and potential litigation involving the Company' as a risk factor, but no specific details of any pending legal proceedings are provided in the filing.
• A monetary judgment, writ, or similar final process against the company or its subsidiaries for more than $50,000 (not covered by insurance) that remains unvacated, unbonded, or unstayed for 30 Trading Days constitutes a 'Triggering Event' for Series B Preferred Stock redemption.

Related Party Transactions

• Faraday Future Intelligent Electric Inc. (Lead Investor) and its Founder and Global Co-CEO YT Jia are investing approximately $34 million in Qualigen Therapeutics, Inc.
• YT Jia will serve as Chief Advisor to Qualigen Therapeutics, Inc.
• Jerry Wang, President of Faraday Future, will be appointed Co-Chief Executive Officer of Qualigen Therapeutics, Inc.
• Koti Meka, CFO of Faraday Future, will be appointed Chief Financial Officer of Qualigen Therapeutics, Inc.
• Faraday Future will have the right to nominate directors to Qualigen Therapeutics, Inc.'s board (initially two, potentially up to four out of seven seats after stockholder approval).
• Faraday Future will have participation rights in Qualigen Therapeutics, Inc.'s future financings as long as its beneficial ownership remains above 5%.
• An Advisory Agreement was entered into with About Investment Pte. Ltd., compensated with 60,257 shares of Common Stock, for capital market advisory services related to the offering and future activities.

Stakeholder Impact

• Shareholders (Existing Common Stockholders): Significant dilution (over 62% beneficial ownership to Lead Investor and founder), major business model change to a high-risk sector, potential for increased volatility, and reduced control over company direction due to governance changes.
• Shareholders (New Investors/Series B Holders): Opportunity to participate in a new crypto/Web3 venture, strong protective provisions (liquidation preference, redemption rights, anti-dilution), and significant influence over company strategy and management.
• Employees: Potential for significant changes in company culture, expertise requirements, and strategic focus as the company pivots from therapeutics to crypto. New management appointments may lead to organizational restructuring.
• Customers (Former Therapeutics): Unclear impact on existing therapeutics business, as the company is pivoting to a new sector. The medical business may continue but with less focus under the new management structure.
• Suppliers/Creditors: Potential changes in business operations and financial risk profile due to the strategic pivot. Existing debt is being paid down with some proceeds, which is positive for those creditors.
• Regulatory Bodies: Increased scrutiny due to the dramatic business model change and entry into the cryptocurrency space, which is subject to evolving regulations.

Next Steps

• Closing of the Offering, expected on or about September 29, 2025.
• Company to use best efforts to obtain Stockholder Approval by October 29, 2025 (or November 28, 2025 if SEC review occurs).
• If Stockholder Approval is not obtained, the Company must call additional stockholder meetings every 90 days until approval is secured.
• Company to file a resale registration statement for Common Stock and Conversion Shares within 45 days of closing.
• Company to use best efforts to have the resale registration statement declared effective within 45 days of filing (or 60 days if SEC reviews).
• Upon Closing, the Board will be reduced to five members, with resignations of Cody Price, Campbell Becher, and Robert Lim, and appointment of Jie Sheng and Chad Chen as Investor Designees.
• Upon Closing, Jiawei Wang will be appointed Co-Chief Executive Officer and Koti Meka as Chief Financial Officer.
• Within 30 days of Closing, the Company will negotiate and aim to enter into an advisory agreement with Mr. YT Jia as Chief Advisor.
• Following Stockholder Approval, the Board size will expand to seven members, and Faraday Future's nomination rights could increase to four directors.
• Upon Stockholder Approval, the Company expects to rebrand as CXC10, focusing fully on crypto and Web3.

Key Dates

Recommendation

This filing describes a highly speculative and risky pivot for Qualigen Therapeutics from a therapeutics company to a cryptocurrency and Web3 focused entity. While the $41 million capital raise is substantial, it comes with significant dilution for existing shareholders (over 62% beneficial ownership to the lead investor and founder). The new business model is in a nascent, volatile, and largely unregulated industry, which is a complete departure from the company's historical expertise. The transfer of substantial control to the lead investor, including board seats and key executive roles with 'sole access' and 'sole authority' over the new crypto business, further diminishes the influence of existing shareholders. The high cost of capital (5.5% cash fee and 6% warrants to the placement agent) and the punitive redemption terms for the Series B Preferred Stock (135% premium upon triggering events) indicate the high-risk nature perceived by the new investors. Given the extreme shift in business, the inherent volatility and regulatory uncertainty of the crypto market, and the significant dilution and loss of control for current shareholders, this transaction presents a substantially elevated risk profile with an uncertain path to profitability, making it a strong sell for seasoned investors.

Keywords

Qualigen Therapeutics, Faraday Future, PIPE, Private Investment in Public Equity, Cryptocurrency, Web3, Strategic Pivot, Series B Preferred Stock, Convertible Preferred Stock, Corporate Governance, Management Change, Nasdaq Listing Rule 5635, Equity Financing, Digital Assets, Blockchain, Investment, QLGN, FFAI, CXC10